Patents by Inventor Joyce D. Fingeroth

Joyce D. Fingeroth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
    Patent number: 9382286
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: July 5, 2016
    Assignees: EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION
    Publication number: 20140336143
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: December 4, 2013
    Publication date: November 13, 2014
    Applicants: GILEAD PHARMASSET LLC, BETH ISRAEL DEACONESS MEDICAL CENTER, EMORY UNIVERSITY
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
    Publication number: 20100168052
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: December 28, 2009
    Publication date: July 1, 2010
    Applicants: Pharmasset, Inc., EMORY UNIVERSITY, BETH ISRAEL DEACONESS MEDICAL CENTER
    Inventors: Raymond F. Schinazi, Junxing Shi, Erik Gustafson, Joyce D. Fingeroth
  • Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
    Patent number: 7638502
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: December 29, 2009
    Assignees: Pharmasset, Inc., Beth Israel Deaconess Medical Center, Emory University
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • Treatment of EBV and KHSV infection
    Patent number: 7211570
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 1, 2007
    Assignees: Pharmasset, Inc., Emory University, Beth Israel Deaconess Medical Center
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
    Publication number: 20030176392
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: December 19, 2002
    Publication date: September 18, 2003
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson